# Islatravir + Lenacapavir Once-Weekly Oral

**ID:** TRT-006
**Year:** 2024
**Source:** ID Week 2024
**Link:** [https://www.aidsmap.com/news/mar-2024/islatravir-plus-lenacapavir-could-be-first-once-weekly-oral-hiv-treatment](https://www.aidsmap.com/news/mar-2024/islatravir-plus-lenacapavir-could-be-first-once-weekly-oral-hiv-treatment)

---

## Abstract

Phase 2 trial showing 94% viral suppression at 48 weeks with novel once-weekly oral combination.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
